Supervisor

Dott.ssa Vittorina Zagonel

Description

An essential component of research conducted at IOV is characterized by innovative clinical studies, precision medicine, and translational studies. Retrospective, observational, and interventional studies aimed at optimizing already available treatments and at developing innovative therapies based on molecular characterization and precision medicine are crucial to producing knowledge on optimal patient treatment. Another essential element is the search for predictive and prognostic factors and the use of patient reported outcomes (PROs) to evaluate the impact of new therapies on patients’ quality of life.

Background

Research at the IOV is characterized by a continuous commitment to promotion and participation in pharmacological and non-pharmacological clinical research protocols. The results obtained to date have allowed us to develop and promote cutting-edge skills in the conception, coordination, and management of clinical and translational research initiatives. Collaboration with many Italian oncology departments guarantees competitive recruitment in international trials with innovative drugs. In the field of oncology, the rapid transfer of innovative therapies to the clinical setting guarantees many patients the opportunity to benefit from new real-time care opportunities. The results obtained must be measured and monitored with retrospective protocols, which are a valuable source of data for exploratory hypotheses to be verified longitudinally. The clinical research line is the point of arrival and departure for translational projects, and it is strictly related to the other IOV research lines.

Rationale

Clinical research is intrinsic to the mission of an IRCCS. The strategic objective is to implement translational research, and to identify predictive response indicators to optimize the type and duration of innovative therapies (e.g. Immunotherapy), in order to guarantee effective and socially sustainable treatments. These aspects cannot be separated from the patient in his or her entirety; prevention, rehabilitation, nursing and psychological support, nutrition, pain relief, and quality of life find a perfect integration in research programs, designed with the same methodological rigor as that for clinical trials.

Global goals

  1. to perform research projects at each decision-making node of the therapeutic-care pathway: molecular characterization of tumors, translational research, personalization of care, quality of life;
  2. to expand non-pharmacological trials; retrospective and outcome analyses such as monitoring and verification of the results obtained;

Expected results

  • Progressive increase in the number of active clinical trials.
  • To design and participate in independent research study proposals and implement leadership of national and international initiatives.
  • To drive translational and non-pharmacological studies, including those aimed to detect predictive indicators of response and use of PROs as a parameter of quality of life.
  • Dissemination of results at national and international level.
  • increased participation, with significant roles for IOV staff, within Italian and international collaborative networks (e.g. cooperative groups, ACC, OECI, EORTC, etc).
Top 15 pubblicazioni 2019 linea 4
TitoloAutoriRivistaIF grezzo
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal CancerKopetz Scott, Grothey Axel, Yaeger Rona, Van Cutsem Eric, Desai Jayesh, Yoshino Takayuki, Wasan Harpreet, Ciardiello Fortunato, Loupakis Fotios, Hong Yong Sang, Steeghs Neeltje, Guren Tormod K, Arkenau Hendrik-Tobias, Garcia-Alfonso Pilar, Pfeiffer Per, Orlov Sergey, Lonardi Sara, Elez Elena, Kim Tae-Won, Schellens Jan H M, Guo Christina, Krishnan Asha, Dekervel Jeroen, Morris Van, Calvo Ferrandiz Aitana, Tarpgaard L S, Braun Michael, Gollerkeri Ashwin, Keir Christopher, Maharry Kati, Pickard Michael, Christy-Bittel Janna, Anderson Lisa, Sandor Victor, Tabernero JosepNEW ENGLAND JOURNAL OF MEDICINE70.67
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaRobert Caroline, Grob Jean J, Stroyakovskiy Daniil, Karaszewska Boguslawa, Hauschild Axel, Levchenko Evgeny, chiarion sileni vanna, Schachter Jacob, Garbe Claus, Bondarenko Igor, Gogas Helen, Mandalá Mario, Haanen John B A G, Lebbé Celeste, Mackiewicz Andrzej, Rutkowski Piotr, Nathan Paul D, Ribas Antoni, Davies Michael A, Flaherty Keith T, Burgess Paul, Tan Monique, Gasal Eduard, Voi Maurizio, Schadendorf Dirk, Long Georgina VNEW ENGLAND JOURNAL OF MEDICINE70.67
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaLarkin James, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Lao Christopher D, Cowey C Lance, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier F, Smylie Michael, Hogg David, Hill Andrew, Márquez-Rodas Ivan, Haanen John, Guidoboni Massimo, Maio Michele, Schöffski Patrick, Carlino Matteo S, Lebbé Céleste, McArthur Grant, Ascierto Paolo A, Daniels Gregory A, Long Georgina V, Bastholt Lars, Rizzo Jasmine I, Balogh Agnes, Moshyk Andriy, Hodi F Stephen, Wolchok Jedd DNEW ENGLAND JOURNAL OF MEDICINE70.67
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trialBonvalot Sylvie, Rutkowski Piotr L., Thariat Juliette, Carrère Sébastien, Ducassou Anne, Sunyach Marie Pierre, Agoston P., Hong Angela, Mervoyer Augustin, Rastrelli Marco, Moreno Victor, Li Rubi K., Tiangco Béatrice, Herraez Antonio Casado, Gronchi Alessandro, Mangel László, Sy-Ortin Teresa, Hohenberger P., de Baère Thierry, Le Cesne Axel, Helfre Sylvie, Saada-Bouzid Esma, Borkowska A., Anghel Rodica, Co Ann, Gebhart Michael, Kantor Guy, Montero A., Loong Herbert H., Vergés Ramona, Lapeire Lore, Dema S., Kacso Gabriel, Austen Lyn, Moureau-Zabotto Laurence, Servois Vincent, Wardelmann Eva, Terrier Philippe, Lazar Alexander J., Bovée Judith V.M.G., Le Péchoux Cécile, Papai ZsusannaLANCET ONCOLOGY35.386
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialFuchs Charles S., Shitara Kohei, Di Bartolomeo Maria, Lonardi Sara, Al-Batran Salah Eddin, Van Cutsem Eric, Ilson David H., Alsina Maria, Chau Ian, Lacy Jill, Ducreux Michel, Mendez Guillermo Ariel, Alavez Alejandro Molina, Takahari Daisuke, Mansoor Wasat, Enzinger Peter C., Gorbounova Vera, Wainberg Zev A., Hegewisch-Becker Susanna, Ferry David, Lin Ji, Carlesi Roberto, Das Mayukh, Shah Manish A., Luft Alexander V., Karaseva Nina A., Kowalyszyn Rubén Dario, Hernandez Carlos Alberto, Csoszi Tibor, De Vita Ferdinando, Pfeiffer Per, Sugimoto Naotoshi, Kocsis Judit, Csilla Andràs, Bodoky Gyorgy, Garnica Jaliffe Georgina, Protsenko Svetlana, Madi Ayman, Wojcik Elzbieta, Brenner Baruch, Folprecht Gunnar, Sarosiek Tomasz, Peltola Katriina Johanna, Bono Peter, Ayala Hubert, Aprile Giuseppe, Gerardo Cardellino Giovanni, Huitzil Melendez Fidel David, Falcone Alfredo, Di Costanzo Francesco, Group RAINFALL StudyLANCET ONCOLOGY35.386
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialLebbé Celeste, Meyer Nicolas, Mortier Laurent, Marquez-Rodas Ivan, Robert Caroline, Rutkowski Piotr, Menzies Alexander M, Eigentler Thomas, Ascierto Paolo A, Smylie Michael, Schadendorf Dirk, Ajaz Mazhar, Svane Inge Marie, Gonzalez Rene, Rollin Linda, Lord-Bessen Jennifer, Saci Abdel, Grigoryeva Elena, Pigozzo JacopoJOURNAL OF CLINICAL ONCOLOGY28.349
Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study GroupGroup on behalf of the EpSSG Radiology, Vaarwerk Bas, Bisogno Gianni, McHugh Kieran, Brisse Hervé J., Morosi Carlo, Corradini Nadège, Jenney Meriel, Orbach Daniel, Chisholm Julia C., Ferrari Andrea, Zanetti Ilaria, De Salvo Gian Luca, van Rijn Rick R., Merks Johannes H.M.JOURNAL OF CLINICAL ONCOLOGY28.349
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 StudyDraaisma Kaspar, Chatzipli Aikaterini, Taphoorn Martin, Kerkhof Melissa, Weyerbrock Astrid, Sanson Marc, Hoeben Ann, Lukacova Slávka, Lombardi Giuseppe, Leenstra Sieger, Hanse Monique, Fleischeuer Ruth, Watts Colin, McAbee Joseph, Angelopoulos Nicos, Gorlia Thierry, Golfinopoulos Vassilis, Kros Johan M, Verhaak Roel G W, Bours Vincent, van den Bent Martin J, McDermott Ultan, Robe Pierre A, French Pim JJOURNAL OF CLINICAL ONCOLOGY28.349
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance TherapyMorano Federica, Corallo Salvatore, Lonardi Sara, Raimondi Alessandra, Cremolini Chiara, Rimassa Lorenza, Murialdo Roberto, Zaniboni Alberto, Sartore-Bianchi Andrea, Tomasello Gianluca, Racca Patrizia, Clavarezza Matteo, Adamo Vincenzo, Perrone Federica, Gloghini Annunziata, Tamborini Elena, Busico Adele, Martinetti Antonia, Palermo Federica, Loupakis Fotios, Milione Massimo, Fucà Giovanni, Di Bartolomeo Maria, de Braud Filippo, Pietrantonio FilippoJOURNAL OF CLINICAL ONCOLOGY28.349
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort ResultsSharma Padmanee, Siefker-Radtke Arlene, de Braud Filippo, Basso Umberto, Calvo Emiliano, Bono Petri, Morse Michael A, Ascierto Paolo A, Lopez-Martin Jose, Brossart Peter, Rohrberg Kristoffer, Mellado Begoña, Fischer Bruce S, Meadows-Shropshire Stephanie, Abdel Saci , Callahan Margaret K, Rosenberg JonathanJOURNAL OF CLINICAL ONCOLOGY28.349
Reply to E. Hindié and K.R. HessLong Georgina V, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandalà Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Hauschild AxelJOURNAL OF CLINICAL ONCOLOGY28.349
Quantitative evidence for early metastatic seeding in colorectal cancerHu Zheng, Ding Jie, Ma Zhicheng, Sun Ruping, Seoane Jose A, Scott Shaffer J, Suarez Carlos J, Berghoff Anna S, Cremolini Chiara, Falcone Alfredo, Loupakis Fotios, Birner Peter, Preusser Matthias, Lenz Heinz-Josef, Curtis ChristinaNATURE GENETICS25.455
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialPietrantonio Filippo, Morano Federica, Corallo Salvatore, Miceli Rosalba, Lonardi Sara, Raimondi Alessandra, Cremolini Chiara, Rimassa Lorenza, bergamo francesca, Sartore-Bianchi Andrea, Tampellini Marco, Racca Patrizia, Clavarezza Matteo, Berenato Rosa, Caporale Marta, Antista Maria, Niger Monica, Smiroldo Valeria, Murialdo Roberto, Zaniboni Alberto, Adamo Vincenzo, Tomasello Gianluca, Giordano Monica, Petrelli Fausto, Longarini Raffaella, Cinieri Saverio, Falcone Alfredo, zagonel vittorina, Di Bartolomeo Maria, de Braud FilippoJAMA Oncology22.416
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.Sledge George W, Toi Masakazu, Neven Patrick, Sohn Joohyuk, Inoue Kenichi, Pivot Xavier, Burdaeva Olga, Okera Meena, Masuda Norikazu, Kaufman Peter A, Koh Han, Grischke Eva-Maria, Conte Pierfranco, Lu Yi, Barriga Susana, Hurt Karla, Frenzel Martin, Johnston Stephen, Llombart-Cussac AntonioJAMA Oncology22.416
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studiesMarmorino F., Rossini D., Lonardi Sara, Moretto R., Zucchelli G., Aprile G., Dell'Aquila E., Ratti M., bergamo francesca, Masi G., Urbano F., Ronzoni M., Libertini M., Borelli B., Randon G., Buonadonna A., Allegrini G., Pella N., Ricci V., Boccaccino A., Latiano T. P., Cordio S., Passardi A., Tamburini E., Boni L., Falcone A., Cremolini C.ANNALS OF ONCOLOGY14.196

Source: IOV Scientific library

Top 15 pubblicazioni 2018 linea 4
TitoloAutoriRivistaIF grezzo
Cabozantinib in patients with advanced and progressing hepatocellular carcinomaAbou-Alfa Ghassan K., Meyer Tim, Cheng Ann Lii, El-Khoueiry Anthony B., Rimassa Lorenza, Ryoo Baek Yeol, Cicin Irfan, Merle Philippe, Chen Yen Hsun, Park Joong Won, Blanc Jean Frederic, Bolondi Luigi, Kl¿¿mpen Heinz Josef, Chan Stephen L., zagonel vittorina, Pressiani Tiziana, Ryu Min Hee, Venook Alan P., Hessel Colin, Borgman-Hagey Anne E., Schwab Gisela, Kelley Robin K.NEW ENGLAND JOURNAL OF MEDICINE79.26
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trialGroup European paediatric Soft tissue sarcoma Study, Bisogno Gianni, Jenney Meriel, Bergeron Christophe, Gallego Melc¿¿n Soledad, Ferrari Andrea, Oberlin Odile, Carli Modesto, Stevens Michael, Kelsey Anna, De Paoli Angela, Gaze Mark N, Martelli Helene, Devalck Christine, Merks Johannes H, Ben-Arush Myriam, Glosli Heidi, Chisholm Julia, Orbach Daniel, Minard-Colin Veronique, De Salvo Gian LucaLANCET ONCOLOGY36.421
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) a multicentre, open-label, randomised phase 3 trialDummer Reinhard, Ascierto Paolo A, Gogas Helen J, Arance Ana, Mandala Mario, Liszkay Gabriella, Garbe Claus, Schadendorf Dirk, Krajsova Ivana, Gutzmer Ralf, chiarion sileni vanna, Dutriaux Caroline, de Groot Jan Willem B, Yamazaki Naoya, Loquai Carmen, Moutouh-de Parseval Laure A, Pickard Michael D, Sandor Victor, Robert Caroline, Flaherty Keith TLANCET ONCOLOGY36.421
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21) a placebo-controlled, phase 3 randomised trialFriedlander Michael, Gebski Val, Gibbs Emma, Davies Lucy, Bloomfield Ralph, Hilpert Felix, Wenzel Lari B., Eek Daniel, Rodrigues Manuel, Clamp Andrew, Penson Richard T., Provencher Diane, Korach Jacob, Huzarski Tomasz, Vidal Laura, Salutari Vanda, Scott Clare, NICOLETTO MARIA ORNELLA, Tamura Kenji, Espinoza David, Joly Florence, Pujade-Lauraine EricLANCET ONCOLOGY36.421
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067) 4-year outcomes of a multicentre, randomised, phase 3 trialHodi Frank Stephen, chiarion sileni vanna, Gonzalez Rene, Grob Jean-Jacques, Rutkowski Piotr, Cowey Charles Lance, Lao Christopher D, Schadendorf Dirk, Wagstaff John, Dummer Reinhard, Ferrucci Pier Francesco, Smylie Michael, Hill Andrew, Hogg David, Marquez-Rodas Ivan, Jiang Joel, Rizzo Jasmine, Larkin James, Wolchok Jedd DLANCET ONCOLOGY36.421
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialDummer R., Ascierto P.A., Gogas H.J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., chiarion sileni vanna, Dutriaux C., de Groot J.W.B., Yamazaki N., Loquai C., Moutouh-de Parseval L.A., Pickard M.D., Sandor V., Robert C., Flaherty K.T.LANCET ONCOLOGY36.421
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224) a non-randomised, open-label phase 2 trialKEYNOTE-224 investigators Gruppo, Zhu Andrew X, Finn Richard S, Edeline Julien, Cattan Stephane, Ogasawara Sadahisa, Palmer Daniel, Verslype Chris, zagonel vittorina, Fartoux Laetitia, Vogel Arndt, Sarker Debashis, Verset Gontran, Chan Stephen L, Knox Jennifer, Daniele Bruno, Webber Andrea L, Ebbinghaus Scot W, Ma Junshui, Siegel Abby B, Cheng Ann-Lii, Kudo MasatoshiLANCET ONCOLOGY36.421
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA) a multicentre, open-label, randomised, controlled, phase 2 trialLOMBARDI GIUSEPPE, De Salvo Gian Luca, Brandes Alba Ariela, Eoli Marica, Rud¿¿ Roberta, Faedi Marina, Lolli Ivan, Pace Andrea, Daniele Bruno, Pasqualetti Francesco, Rizzato Simona, Bellu Luisa, Pambuku Ardi, Farina Miriam, Magni Giovanna, Indraccolo Stefano, Gardiman Marina Paola, Soffietti Riccardo, zagonel vittorinaLANCET ONCOLOGY36.421
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC) a final analysis of a phase 3, randomised, placebo-controlled studyRimassa Lorenza, Assenat Eric, Peck-Radosavljevic Markus, Pracht Marc, zagonel vittorina, Mathurin Philippe, Rota Caremoli Elena, Porta Camillo, Daniele Bruno, Bolondi Luigi, Mazzaferro Vincenzo, Harris William, Damjanov Nevena, Pastorelli Davide, Reig Mar¿¿a, Knox Jennifer, Negri Francesca, Trojan J¿¿rg, L¿¿pez L¿¿pez Carlos, Personeni Nicola, Decaens Thomas, Dupuy Marie, Sieghart Wolfgang, Abbadessa Giovanni, Schwartz Brian, Lamar Maria, Goldberg Terri, Shuster Dale, Santoro Armando, Bruix JordiLANCET ONCOLOGY36.421
BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid CancerWang Fei, Zhao Shihua, Shen Xiaopei, Zhu Guangwu, Liu Rengyun, Viola David, Elisei Rossella, Puxeddu Efisio, Fugazzola Laura, Colombo Carla, Jarzab Barbara, Czarniecka Agnieszka, Lam Alfred K, Mian Caterina, Vianello Federica, Yip Linwah, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, O'Neill Christine J, Sywak Mark S, Clifton-Bligh Roderick, Bendlova Bela, S¿¿korov¿¿ Vlasta, Wang Yangang, Xing MingzhaoJOURNAL OF CLINICAL ONCOLOGY26.36
Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative GroupsWalterhouse David O, Barkauskas Donald A, Hall David, Ferrari Andrea, De Salvo Gian Luca, Koscielniak Ewa, Stevens Michael C G, Martelli H¿¿l¿¿ne, Seitz Guido, Rodeberg David A, Shnorhavorian Margarett, Dasgupta Roshni, Breneman John C, Anderson James R, Bergeron Christophe, Bisogno Gianni, Meyer William H, Hawkins Douglas S, Minard-Colin VeroniqueJOURNAL OF CLINICAL ONCOLOGY26.36
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal CancerOverman Michael J, Lonardi Sara, Wong Ka Yeung Mark, Lenz Heinz-Josef, Gelsomino Fabio, Aglietta Massimo, Morse Michael A, Van Cutsem Eric, McDermott Ray, Hill Andrew, Sawyer Michael B, Hendlisz Alain, Neyns Bart, Svrcek Magali, Moss Rebecca A, Ledeine Jean-Marie, Cao Z Alexander, Kamble Shital, Kopetz Scott, Andr¿¿ ThierryJOURNAL OF CLINICAL ONCOLOGY26.36
FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant TrialInvestigators TOSCA, Sobrero Alberto, Lonardi Sara, Rosati Gerardo, Di Bartolomeo Maria, Ronzoni Monica, Pella Nicoletta, Scartozzi Mario, Banzi Maria, Zampino Maria Giulia, Pasini Felice, Marchetti Paolo, Cantore Maurizio, Zaniboni Alberto, Rimassa Lorenza, Ciuffreda Libero, Ferrari Daris, zagonel vittorina, Maiello Evaristo, Barni Sandro, Rulli Eliana, Labianca RobertoJOURNAL OF CLINICAL ONCOLOGY26.36
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaHauschild Axel, Dummer Reinhard, Schadendorf Dirk, Santinami Mario, Atkinson Victoria, Mandal¿¿ Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Schachter Jacob, Lesimple Thierry, Plummer Ruth, Dasgupta Kohinoor, Haas Tomas, Shilkrut Mark, Gasal Eduard, Kefford Richard, Kirkwood John M, Long Georgina VJOURNAL OF CLINICAL ONCOLOGY26.36
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumabvan Dijk Erik, Biesma Hedde D, Cordes Martijn, Smeets Dominiek, Neerincx Maarten, Das Sudipto, Eijk Paul P, Murphy Verena, Barat Anna, Bacon Orna, Prehn Jochen H M, Betge Johannes, Gaiser Timo, Fender Bozena, Meijer Gerrit A, McNamara Deborah A, Klinger Rut, Koopman Miriam, Ebert Matthias P A, Kay Elaine W, Hennessey Bryan T, Verheul Henk M W, Gallagher William M, O'Connor Darran P, Punt Cornelis J A, Loupakis Fotios, Lambrechts Diether, Byrne Annette T, van Grieken Nicole C T, Ylstra BaukeJOURNAL OF CLINICAL ONCOLOGY26.36

Source: IOV Scientific library